Status
Conditions
Treatments
About
The three-year interventional study has the following objectives:
The study aims to assess the prevalence of sarcopenia in menopausal women receiving hormone replacement therapy or not compared with pre-menopausal women. The study population will be divided into groups according to the intake or not of hormonal therapy of menopause as per normal clinical practice and the menopausal state:
GROUP A - menopausal patient taking hormone therapy GROUP B - menopausal patient not taking hormone therapy GROUP C - pre-menopausal patients who do not take hormonal products The primary objective is to compare the strength and muscle mass outcomes of HRT in menopausal women compared with those who do not use it and women in pre-menopausal age. Survey methods such as SARC-F, Handgrip test, Chair stand test and bio impedance
Full description
The present one-center cross-sectional observational study involves the recruitment of patients attending the O.U. of Gynecology and Pathophysiology of Human Reproduction in menopause who take or do not take hormone replacement therapy at the time of the first visit and women in pre-menopause but similar age group compared to the first group.
Patients will be asked to participate in this study during the outpatient follow-up visit.
The study will involve data collection through consultation of health records.
The objectives of the study will therefore be achieved by analysing certain parameters that can be deduced from the medical records of the subjects in the study:
Questionnaire SARC-F Handgrip test Chair stand test bioimpedance Study population
Inclusion criteria:
Visits and evaluations Visits and assessment scheme Each patient will be invited to participate in this study at the usual outpatient checkup according to current clinical practice. Patients will be free to decide whether or not to participate in the study
Information will be collected from the patients attending the U.O. of Gynecology and Pathophysiology of Human Reproduction in menopause who take or do not take hormone replacement therapy at the time of the first visit and women in pre-menopausemenopause but similar age group compared to the first group.
An estimated sample of 180 subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients for whom informed consent has been obtained.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
180 participants in 1 patient group
Loading...
Central trial contact
Maria C Meriggiola, MD; Giulia Gava, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal